Cladribine, a synthetic deoxyadenosine analog, is an oral immunomodulatory agent that produces targeted, sustained reduction of T and B lymphocytes. This mechanism of action provides the rationale ...

For this technology appraisal, the committee evaluated cladribine only for people with active RRMS. This is because cladribine has already been evaluated for the highly active and rapidly evolving ...

Cladribine can help people with the active relapsing-remitting version of the disease, as well as more severe, highly active ...

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 /BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...

The drug, cladribine - also known as Mavenclad and manufactured by Merck - has recently received the green light from the ...

The Geneva-based company has been operating under the radar since being formed to develop CRD1, a new oral formulation of the long-established drug chemotherapy cladribine which has been used ...

New guidance (PDF) from health technology assessment (HTA) agency NICE means that Mavenclad (cladribine) will soon be an option for people with active relapsing-remitting MS who are having ...

However, as most data is registry-based and previous trials did not directly compare aHSCT with the most efficacious DMTs, Alemtuzumab, Ocrelizumab, Cladribine and Ofatumumab, questions remain over ...

BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party ...

VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...